欧洲呼吸学会
期刊
会议
图书
作者:Marie-Camille Chaumais , Laurent Savale ...
来源:[J].European Respiratory Journal(IF 6.355), 2017, Vol.50 (1)
摘要:This study aimed to describe the long-term outcomes of pulmonary arterial hypertension (PAH) induced by dasatinib.(#br)21 incident, right heart catheterisation-confirmed cases of dasatinib-induced PAH were identified from the French Pulmonary Hypertension Registry. Clinical ...
作者:Marie-Camille Chaumais , Marc Humbert ...
来源:[J].European Respiratory Journal(IF 6.355), 2019, Vol.53 (5)
摘要:The pathophysiology of pulmonary arterial hypertension (PAH) induced by protein kinase inhibitors (PKIs) remains unclear. To gain knowledge into this rare and severe pathology we performed a study combining a pharmacovigilance approach and the pharmacodynamic properties of PKIs.(...
作者:... Gerald Simonneau , Marc Humbert , Marie-Camille Chaumais
来源:[J].European Respiratory Journal(IF 6.355), 2015, Vol.46 (4), pp.1211-1214
摘要:In the scientific and medical community, it is recognised that exposure to certain drugs could promote the development of pulmonary arterial hypertension (PAH). These drugs, with a “class effect” (amphetamine-like) or not (dasatinib), are prescribed for serious (dasatinib, i...
作者:Marie-Camille Chaumais , Olivier Sitbon
来源:[J].European Respiratory Journal(IF 6.355), 2015, Vol.46 (6), pp.1851-1853
摘要:We read with interest the correspondence by Prella and colleagues reporting yet another case of pulmonary arterial hypertension (PAH) suspected to be induced by long-term interferon (IFN)-β therapy in a patient with multiple sclerosis. As discussed by Prella and colleagues, ...
作者:Marie-Camille Chaumais , Christophe Guignabert ...
来源:[J].European Respiratory Journal(IF 6.355), 2016, Vol.48 (5), pp.1517-1519
摘要:Tyrosine kinase inhibitors (TKIs) targeting BCR/ABL such as imatinib, nilotinib, dasatinib, bosutinib and ponatinib have revolutionised the management of patients with chronic myeloid leukaemia (CML) [1]. Pleural effusions and pulmonary arterial hypertension (PAH) have been ...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×